Sun Pharmaceutical Industries (NSE: SUNPHARMA) gained 2.03% on Wednesday, pushing the stock back toward ₹1,700 and reviving bullish interest after weeks of range-bound movement. The bounce comes just in time, with broader markets steadying and traders rotating back into defensive names.
The rally follows a relatively quiet stretch for Sun Pharma, where the stock drifted lower from its April highs above ₹1,850. But today’s push signals that buyers are re-entering near the lower end of the short-term channel, with ₹1,680–₹1,700 now shaping up as a key battleground.
The chart shows a solid recovery off the ₹1,650 zone, which acted as support in early May. While the larger trend remains bullish, recent price action has been consolidative, not corrective.
The daily structure is beginning to tilt upward again, but bulls still need a decisive break above ₹1,740 to call this more than a relief rally.
Momentum looks better than it did a week ago. If Sun Pharma can close above ₹1,740 this week, the path toward ₹1,800 opens up quickly. Beyond that, a retest of the April high near ₹1,850 isn’t off the table, but it depends on broader sector participation and fresh institutional buying.
For now, this bounce looks like the start of a recovery, not a breakout. But in a market rotating into pharma, Sun is starting to feel relevant again.
This article was originally published on InvestingCube.com. Republishing without permission is prohibited.
This post was last modified on May 29, 2025, 15:35 BST 15:35